-
Intradermal ChAdOX1 vaccine following two coronavac shots: A case report
- Back
Document Title
Intradermal ChAdOX1 vaccine following two coronavac shots: A case report
Author
Singhatiraj E.,Pongpirul K.,Jongkaewwattana A.,Hirankarn N.
Name from Authors Collection
Affiliations
Department of Medicine, Bumrungrad International Hospital, Bangkok, 10110, Thailand; Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States; National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani12120, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
Type
Article
Source Title
Vaccines
ISSN
2076393X
Year
2021
Volume
9
Issue
9
Open Access
All Open Access, Gold, Green
Publisher
MDPI
DOI
10.3390/vaccines9090990
Abstract
Inactivated SARS-CoV-2 vaccines are used in many countries with uncertain immunogen-icity. Intradermal ChAdOx1 has been proposed as a resource-efficient heterologous third booster shot. A 52-year-old healthy male healthcare professional had received two intramuscular Coro-naVac shots on 21 April and 23 May 2021, and volunteered to take a 0.1 mL ChAdOx1 vaccine intradermally on 29 June 2021, with minimal local reactions. The declining IgG levels against spike protein from the two CoronaVac shots increased to higher than 10,000 AU/mL two weeks after the intradermal ChAdOx1. Moreover, the neutralizing antibody increased from 66.77% to almost 100%. A ratio of 6.6:9.7 of IgA:IgG was observed. The 50% pseudovirus neutralization titer (PVNT50) against lentiviral pseudovirus bearing a codon-optimized spike gene (wild type, alpha, beta, and delta) were 1812.42, 822.99, 1025.42, 1347.13, respectively. The SARS-CoV-2-specific T cells to spike protein–peptide pools (532–788 SFU/106 PBMCs) were detected. In conclusion, the antibody and cellular responses to the intradermal ChAdOx1, as a third booster dose in a healthy volunteer who received two intramuscular CoronaVac shots, revealed a dramatic increase in the total antibodies, including IgG, IgA, as well as T cell responses against spike protein. The immune response from intradermal ChAdOx1 should be further investigated in a larger population. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Industrial Classification
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Knowledge Taxonomy Level 3
License
CC BY-NC-ND
Rights
Elsevier B.V.
Publication Source
Scopus